📍 Whitefield, Bengaluru
HOD & Senior Consultant · Surgical Oncology
Consultation by Appointment
Two treatments for cancer that has spread to the lining of the abdomen
The two treatments generally serve different patients, and many uses of PIPAC are still being studied.
HIPEC (hyperthermic intraperitoneal chemotherapy) is a specialized cancer treatment in which heated chemotherapy is delivered directly into the abdomen during surgery, with the goal of destroying microscopic cancer cells that may remain after visible tumors are removed. It is typically combined with cytoreductive surgery (CRS) and is used for selected patients with peritoneal cancers such as appendiceal cancer, colorectal cancer with peritoneal metastases, ovarian cancer, and peritoneal mesothelioma.
This guide answers the questions patients ask most often, from highest-interest topics to more detailed concerns, to help you prepare for a conversation with your cancer care team.
In this guide: What HIPEC is and how it works | Who may qualify | Success rate and survival | The procedure and hospital stay | Risks and side effects | Recovery | Cost and insurance | Alternatives and choosing a specialist. For an overview, see the HIPEC Patient Guide.
| Topic | Overview |
|---|---|
| Full name | Hyperthermic Intraperitoneal Chemotherapy |
| Also called | CRS-HIPEC, heated chemotherapy surgery, peritoneal surface malignancy treatment |
| Delivered | Directly into the abdominal cavity, usually right after cytoreductive surgery |
| Temperature | About 41–43 °C (106–109 °F) |
| Perfusion time | Typically 30–90 minutes |
| Total operating time | Often 6–12 hours, depending on extent of disease |
| Typical hospital stay | About 10–21 days |
| Recovery | Commonly 2–3 months or longer |
HIPEC is a heated chemotherapy treatment circulated through the abdominal cavity during surgery, designed to destroy cancer cells that may remain on the peritoneum, the thin lining of the abdomen, after visible tumors have been removed.
The name breaks down as follows:
Key points about how HIPEC is used:
HIPEC combines heat with high-dose chemotherapy delivered directly to the tumor-bearing surfaces of the abdomen, which is intended to increase drug exposure at the tumor site while limiting exposure to the rest of the body.
Heat and chemotherapy are thought to work together in several ways:
Cytoreductive surgery removes visible tumors from the abdomen, while HIPEC is the heated chemotherapy wash that follows to treat microscopic cancer cells; the two are usually combined as CRS-HIPEC.
| Feature | Cytoreductive Surgery (CRS) | HIPEC |
|---|---|---|
| Purpose | Remove all visible tumor | Treat microscopic cancer cells |
| Method | Surgical removal (peritonectomy and organ resections as needed) | Heated chemotherapy circulated in the abdomen |
| Timing | First step | Second step, same operation |
| Duration | Several hours | About 30–90 minutes |
| Used alone? | Sometimes, in select cases | Generally not used without CRS |
HIPEC is heated chemotherapy given directly into the abdomen in a single session during surgery, whereas regular chemotherapy is usually given through a vein over repeated cycles and circulates throughout the entire body.
| Feature | HIPEC | Standard IV Chemotherapy |
|---|---|---|
| Route | Directly into abdominal cavity | Into a vein (systemic) |
| Temperature | Heated (41–43 °C) | Body temperature |
| Frequency | Usually one session | Repeated cycles over months |
| Drug concentration at peritoneum | Very high | Lower |
| Systemic side effects | Often fewer or milder | More common (hair loss, nausea, low blood counts) |
Commonly used HIPEC drugs include cisplatin, mitomycin C, and oxaliplatin, with the choice depending on the type of cancer being treated and the protocol of the treating center.
| Drug | Commonly Used For |
|---|---|
| Mitomycin C | Appendiceal cancer, pseudomyxoma peritonei, colorectal cancer |
| Cisplatin | Ovarian cancer, peritoneal mesothelioma, gastric cancer |
| Oxaliplatin | Colorectal and appendiceal cancers |
| Doxorubicin (with cisplatin) | Peritoneal mesothelioma, some sarcomas |
Your surgical oncologist selects the drug, dose, and duration based on:
HIPEC is most commonly used for cancers that have spread to or started in the peritoneum, including appendiceal cancer, pseudomyxoma peritonei, peritoneal mesothelioma, colorectal cancer with peritoneal metastases, and ovarian cancer, in carefully selected patients.
| Cancer Type | Role of CRS-HIPEC |
|---|---|
| Appendiceal cancer / pseudomyxoma peritonei | Widely accepted option at specialized centers |
| Peritoneal mesothelioma | Established option for selected patients |
| Colorectal cancer with peritoneal metastases | Option for carefully selected patients with limited disease |
| Ovarian cancer | Randomized evidence supports use at interval surgery in advanced disease; research ongoing in other settings |
| Gastric (stomach) cancer | Considered investigational or used in select cases at expert centers |
| Other rare peritoneal tumors and some sarcomas | Individualized, case by case |
You may be considered for HIPEC if your cancer is mainly confined to the abdomen, all visible disease is expected to be removable, and you are fit enough for a major operation; the final decision is made by a specialist team.
Doctors commonly evaluate:
To support this decision:
The Peritoneal Cancer Index is a scoring system from 0 to 39 that measures how much cancer is present in the abdomen, and a lower score is generally associated with better outcomes after HIPEC.
How the score is calculated:
| PCI Score | General Meaning |
|---|---|
| 0–10 | Limited disease; complete cytoreduction is often more achievable |
| 11–20 | Moderate disease; candidacy depends on cancer type and tumor biology |
| 21–39 | Extensive disease; higher surgical risk and less likely benefit for many cancers |
People with widespread cancer outside the abdomen, disease that cannot be completely removed, or medical conditions that make major surgery unsafe may not be suitable for HIPEC, although each case is assessed individually.
Factors that may make HIPEC less suitable:
If you were told you are not a candidate:
Outcomes after HIPEC vary widely by cancer type and by how completely visible tumor can be removed, with the most favorable long-term survival reported in low-grade appendiceal cancer and pseudomyxoma peritonei, and more modest but meaningful benefit reported in selected colorectal, ovarian, and mesothelioma cases.
| Cancer Type | Approximate 5-Year Survival* |
|---|---|
| Low-grade appendiceal / pseudomyxoma peritonei | Reported at roughly 70–90% with complete cytoreduction |
| High-grade appendiceal cancer | Lower; frequently reported at 20–50% |
| Peritoneal mesothelioma | Commonly reported at 40–50% in selected patients |
| Colorectal peritoneal metastases | Roughly 30–40% in highly selected patients |
| Ovarian cancer | Varies; improved median survival reported in a randomized trial at interval surgery |
How to read these numbers:
HIPEC may lead to long-term remission in some patients, particularly those with low-grade appendiceal cancer or pseudomyxoma peritonei who undergo complete cytoreduction, but for many other cancers it is intended to control disease and extend survival rather than guarantee a cure.
Factors associated with more favorable outcomes:
Evidence differs by cancer type: a randomized trial in ovarian cancer reported improved survival when HIPEC was added at interval cytoreductive surgery, while a major randomized trial in colorectal peritoneal metastases did not show a clear overall survival benefit from adding HIPEC to surgery.
What key studies reported:
Because evidence differs by cancer, ask your surgeon how these findings apply to your exact diagnosis.
Cancer can return after HIPEC, most often within the abdomen, which is why regular follow-up with imaging and blood tests is a standard part of care.
Recurrence risk is influenced by:
If cancer returns, options may include:
HIPEC is performed under general anesthesia immediately after the surgeon removes visible tumors, with heated chemotherapy circulated through the abdomen using a specialized pump and heat-exchange system.
| Step | Phase | What Happens | Approx. Time |
|---|---|---|---|
| 1 | Anesthesia and monitoring | General anesthesia, monitoring lines, and pain-control planning (often epidural or regional block) | 30–60 minutes |
| 2 | Cytoreductive surgery | Visible tumors removed; affected peritoneum, omentum, or organ segments resected as needed | Roughly 3–10 hours |
| 3 | HIPEC delivery | Catheters and temperature probes placed; warmed chemotherapy circulated in the abdomen | 30–90 minutes |
| 4 | Drainage and washout | Chemotherapy solution drained and abdomen rinsed | About 15–30 minutes |
| 5 | Reconstruction and closure | Bowel reconnection or ostomy if needed, drains placed, incision closed | 1–2 hours |
CRS-HIPEC typically takes about 6 to 12 hours, although the heated chemotherapy portion itself usually lasts around 30 to 90 minutes.
| Component | Typical Duration |
|---|---|
| Anesthesia preparation | 30–60 minutes |
| Cytoreductive surgery | Roughly 3–10 hours |
| Heated chemotherapy (HIPEC) | 30–90 minutes |
| Reconstruction and closure | 1–2 hours |
| Total operating time | Often 6–12 hours |
Duration mainly depends on:
Most patients stay in the hospital for about 10 to 21 days after HIPEC, including one to a few days in intensive care or a high-dependency unit, though timing varies with the extent of surgery and recovery.
| Recovery Phase | Typical Timeline |
|---|---|
| Intensive care / close monitoring | 1–3 days |
| Return of bowel function | 5–10 days |
| Start of oral diet | Gradual, often days 3–7 or later |
| Total hospitalization | About 10–21 days |
HIPEC involves a major abdominal operation, so some pain is expected, but it is managed with a multi-layered plan designed to keep discomfort controlled so patients can move and breathe more easily during recovery.
Pain control commonly includes:
To help your team manage pain, report uncontrolled pain promptly, since good pain control supports recovery and may lower the risk of complications such as pneumonia.
Preparing for HIPEC generally means optimizing nutrition, fitness, and medical conditions in advance, following your surgical team’s instructions, and arranging support at home.
| Timeframe | Action | Purpose |
|---|---|---|
| Weeks before | Complete staging tests (CT, MRI, labs, tumor markers, sometimes laparoscopy) | Confirm extent of disease and candidacy |
| Weeks before | Improve nutrition and treat anemia; consult a dietitian | Support healing and lower complication risk |
| Weeks before | Stop smoking and limit alcohol | Reduce lung and wound complications |
| Weeks before | Daily walking and breathing exercises (prehabilitation) | Build strength and lung capacity |
| 1–2 weeks before | Review medications, especially blood thinners and diabetes drugs | Plan safe adjustments with your team |
| Before admission | Arrange caregiver help and time off work | Prepare for a long recovery |
| Before admission | Meet the ostomy nurse if an ostomy is possible | Learn what to expect |
HIPEC is a major, complex operation with meaningful risks, but at experienced high-volume centers serious complications occur in a minority of patients and treatment-related mortality is generally reported in the range of roughly 1–5%.
Complications that can occur include:
Factors associated with lower risk:
HIPEC chemotherapy side effects are often less severe than those of systemic chemotherapy but can include low blood counts, fatigue, nausea, and, depending on the drug, kidney or nerve effects.
| Side Effect | What to Know |
|---|---|
| Fatigue | Very common; may last weeks to months |
| Nausea and poor appetite | Common in the first weeks |
| Low blood counts | Can occur, particularly with mitomycin C |
| Kidney stress | Monitored closely, especially with cisplatin; hydration is used |
| Hair loss | Less common than with IV chemotherapy |
| Neuropathy | Possible with oxaliplatin |
Contact your surgical team promptly if you develop fever, worsening abdominal pain, persistent vomiting, wound changes, shortness of breath, leg swelling, or reduced urine output after HIPEC, and seek emergency care for severe symptoms.
| Symptom | Urgency | Suggested Action |
|---|---|---|
| Temperature of 100.4 °F (38 °C) or higher | Urgent | Call your surgical team the same day |
| Severe or worsening belly pain or swelling | Urgent | Call your team immediately |
| Vomiting that prevents keeping down fluids | Urgent | Call your team; may need evaluation for dehydration or obstruction |
| Chest pain, shortness of breath, or a swollen painful leg | Emergency | Seek emergency care |
| Sudden change or stop in ostomy output | Urgent | Call your team |
| Dizziness and very little urine | Urgent | Call your team; possible dehydration |
Recovery after HIPEC typically takes about 2 to 3 months for return to daily activities, although some patients need 6 months or longer to regain their previous energy and strength.
| Time After Surgery | What to Expect |
|---|---|
| Weeks 1–3 | Hospital stay, gradual return of bowel function, daily walking |
| Weeks 3–6 | Home recovery; fatigue, small frequent meals, lifting limits |
| Weeks 6–12 | Increasing activity; many patients return to light work or usual routines |
| 3–6 months | Strength and stamina continue to improve |
After HIPEC, most patients begin with clear liquids and progress to small, frequent, high-protein meals as bowel function returns, guided by a dietitian.
| Stage | Typical Approach | Notes |
|---|---|---|
| Early hospital days | Clear liquids, then full liquids | Advanced as bowel function returns |
| Late hospital stay | Soft, low-residue foods in small portions | Watch for nausea or bloating |
| Early home recovery | 5–6 small meals daily, protein-focused | Eggs, fish, poultry, dairy, protein shakes |
| Ongoing | Add fiber gradually; stay hydrated | Report weight loss or poor appetite early |
Many patients return to desk work or usual daily activities about 2 to 3 months after HIPEC surgery, depending on the extent of surgery, any additional treatment, and how they feel.
| Activity | Typical Timing | Notes |
|---|---|---|
| Walking | From the first days after surgery | Encouraged daily |
| Driving | Once off opioid pain medicine and able to brake safely | Confirm with your surgeon |
| Heavy lifting (over about 10 lb) | Often avoided for 6–8 weeks | Follow your surgeon’s instructions |
| Desk work | Often 2–3 months | Varies with recovery |
| Physically demanding work | May take longer | Discuss with your team |
Follow-up after HIPEC generally includes clinic visits, blood tests including tumor markers, and CT or MRI scans, often every 3 to 6 months for the first years, to detect recurrence early.
| Interval | Typical Assessments | Purpose |
|---|---|---|
| First visit (about 2–4 weeks) | Wound check, symptoms, nutrition review | Confirm safe early recovery |
| Every 3–6 months (early years) | Exam, tumor markers, CT or MRI | Detect recurrence early |
| Yearly, long term | Imaging and labs as advised | Ongoing surveillance |
Additional treatment may include:
HIPEC surgery is expensive, with total hospital charges in the United States commonly reported in the range of roughly $80,000 to more than $200,000, depending on the hospital, length of stay, complications, and extent of surgery.
| Cost Component | What It Typically Includes |
|---|---|
| Surgical and anesthesia fees | Surgeon, assistant surgeons, anesthesiologist, operating room |
| Chemotherapy and perfusion | Drugs, perfusion pump, heat-exchange equipment |
| Inpatient stay | ICU and hospital days, nursing care, medications |
| Diagnostics | Imaging, laboratory tests, pathology |
| Follow-up care | Clinic visits and surveillance scans |
To plan for costs:
Coverage varies by insurer and diagnosis: many plans, including Medicare and many commercial plans, cover HIPEC for accepted indications such as appendiceal cancer and pseudomyxoma peritonei, while coverage for other cancers often requires prior authorization and medical necessity review.
| Step | Action | Who Typically Helps |
|---|---|---|
| 1 | Request prior authorization early | Surgeon’s office or hospital |
| 2 | Confirm network status or request an out-of-network exception | Insurer and patient navigator |
| 3 | Ask for a peer-to-peer review if a claim is denied | Treating surgeon |
| 4 | File a formal appeal with a letter of medical necessity | Surgeon and patient |
| 5 | Ask about financial assistance and travel or lodging support | Hospital financial counselor or social worker |
Alternatives to HIPEC may include systemic chemotherapy, targeted therapy, immunotherapy, cytoreductive surgery alone, palliative care, and, at some centers, newer approaches such as PIPAC (pressurized intraperitoneal aerosol chemotherapy).
| Option | May Be Considered For |
|---|---|
| Systemic chemotherapy | Widespread disease or patients unfit for major surgery |
| Targeted therapy / immunotherapy | Tumors with specific genetic markers |
| CRS without HIPEC | Selected patients, based on evidence and surgeon judgment |
| EPIC (early postoperative intraperitoneal chemotherapy) | Used at some centers after surgery |
| PIPAC | Investigational or select cases where CRS is not possible |
| Palliative and supportive care | Symptom relief and quality of life |
Learn more about PIPAC in our PIPAC treatment guide.
Patients are generally advised to consider a high-volume cancer center with a fellowship-trained surgical oncologist who performs cytoreductive surgery and HIPEC regularly and offers a full multidisciplinary team.
| Topic | Question to Ask | Why It Matters |
|---|---|---|
| Experience | How many CRS-HIPEC procedures do you perform each year? | Volume is associated with outcomes |
| Outcomes | What are your center’s complication and mortality rates? | Sets realistic expectations |
| Expected result | What completeness of cytoreduction do you expect for my case? | Influences prognosis |
| Support team | Do you have a dedicated ICU, nutrition, and ostomy team? | Supports recovery |
| Planning | Will my case be reviewed by a multidisciplinary tumor board? | Confirms team-based decisions |
| Research | Are clinical trials available for my cancer? | May offer additional options |
Search terms that may help you locate specialized programs:
Clinical trials continue to study HIPEC in stomach, ovarian, and colorectal cancers and with new drug combinations, and patients can ask their surgeon or search a registry such as ClinicalTrials.gov.
Trials may study:
Where to look for trials:
